



BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015. Fax : 0731-2723017
Tel. : 0731-2723016, 4066516 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com
Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)
Tel. : 0731-2426700, 2420926, 2524003, Fax : 0731-2420926 • CIN : L24233MP1985PLC002709

Date:10/08/2016

To, The Company Secretary, Corporate Compliance Department The National Stock Exchange of India Limited Bandra Kurla Complex, Mumbai	To, The Company Secretary Corporate Compliance Department BSE Limited Dalal Street, P.J. Tower, Mumbai
--	--

Sub: Approval of Un Audited Financial Result for the quarter ended on 30th June,2016 and Limited Review Report thereon

Scripe Code: 524396; Sripe Id: BIOFILCHEM

Dear Sir/Madam

With reference to the above-mentioned subject in meeting of the Board of the Directors of the Company held on today, has approved the Un Audited Financial Result for the quarter ended on 30th June ,2016 and Limited Review Report thereon.

Copy of audited financial result along with Limited Review Report is enclosed with this letter and copy of the same is also available on website of the Company. i.e www.biofilgroup.net

This is for your information and record.

Thanking you,

Yours Faithfully
For Biofil Chemicals and Pharmaceuticals Limited

Ramesh Shah
Managing Director
(DIN No. 00028819)



Part	Particulars	(Rs in Lakhs) (Except EPS & Number of Shares)			
		3 months quarter ended 30/06/2016	3 Months quarter ended 31/03/2016	Preceding 3 months quarter ended 30/06/2015	Audited for the year ended 31/03/2016
	(Refer Notes Below)	Reviwed	(Audited)	Reviwed	(Audited)
1	Income from operations				
	(a) Net sales/ income from operations (Net of Excise duty)	31.79	287.54	67.40	1085.65
	(b) Other operating income	1.13	234.59	1.70	251.65
	Total income from operations (net)	32.93	522.13	69.10	1337.30
2	Expenses				
	(a) Cost of materials consumed	17.19	47.26	30.54	121.34
	(b) Purchases of stock-in-trade	4.80	1.90	18.28	932.53
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(11.25)	285.07	(6.22)	0.58
	(d) Employee benefits expense	4.57	27.97	5.46	48.23
	(e) Depreciation and amortisation expense	6.53	6.70	6.76	26.49
	(f) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	4.82	85.45	5.25	127.42
	Total expenses	26.65	454.34	60.07	1256.58
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	6.28	67.78	9.03	80.71
4	Other income	-	7.98	0.00	32.55
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	6.28	75.76	9.03	113.26
6	Finance costs	3.75	3.97	3.72	15.19
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 + 6)	2.53	71.79	5.31	98.07
8	Exceptional items		1.12		1.12
9	Profit / (Loss) from ordinary activities before tax (7 + 8)	2.53	70.67	5.31	96.95
10	Tax expense		18.69		18.69
11	Net Profit / (Loss) from ordinary activities after tax (9 + 10)	2.53	51.98	5.31	78.26
12	Minority interest *				
13	Net profit/(loss) after taxes minority interest and share of profit/ (loss) of associates (13+14+ 15)	2.53	51.98	5.31	78.26
14	Paid up Equity Share Capital (Face value of the share shall be indicated)	1627.38	1627.38	1627.38	1627.38
15	Reserve excluding Revaluation Reserve as per the Balance Sheet of previous accounting year				(913.35)
16.i	Earnings per share (before extraordinary items)				
	(of Rs. 10/- each) (not annualised):				
	(a) Basic	0.02	0.32	0.03	0.48
	(b) Diluted	0.02	0.32	0.03	0.48
16.ii	Earnings per share (after extraordinary items)				
	(of Rs. 10/- each) (not annualised):	0.02	0.32	0.03	0.48
	(a) Basic	0.02	0.32	0.03	0.48
	(b) Diluted				

See accompanying note to the financial results

Note :

1. The above Un-audited Financial Results were reviewed by Audit Committee and approved by Board of Directors in their meeting held on 10th August 2016.
2. The Company has been engaged in Pharmaceutical, chemicals and Plastic business accordingly separate segment under Accounting Standard -AS 17 reported.
3. The Statutory auditors have carried out a limited review of the result for quarter ended 30th June 2016.
4. Figures pertaining to previous periods have been regrouped and rearranged wherever necessary.
5. The aforesaid Un-audited financial Results will be uploaded on the Company's website www.biofilgroup.net and will also be available on the websites of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com for the benefit of shareholders and investors

Date : 10-08-2016

Place : Indore


For Biofil Chemicals & Pharmaceuticals Limited



RAMESH SHAH

MANAGING DIRECTOR

DIN: 00028819



BIOFIL CHEMICALS & PHARMACEUTICALS LTD.
CIN NO. L24233MP1985PLC002709

Segmentwise Revenue, Results and Capital Employed for Quarter ended 30th June 2016

(Rs in Lakhs)


S.No.	Segment Revenue	Quarter Ended			Year Ended
		June 30 ,	March 31,	June 30 ,	31 March
		2016	2016	2015	2016
		Reviewed	Audited	Reviewed	Audited
1	Segment Revenue				
	Pharma Unit	6.16	479.52	16.03	1160.00
	Chemicals Division	25.63	33.01	42.89	134.524
	Plastic Division	0.00	6.51	8.48	22.624
	Other	1.13	11.06	1.70	52.696
	Gross Turnover	32.93	530.11	69.10	1369.85
2	Segment Results				
	Pharma Unit	4.44	139.00	3.21	148.07
	Chemicals Division	5.53	(63.77)	8.58	(32.02)
	Plastic Division	(3.69)	(4.10)	(2.75)	(7.39)
	Other	0.00	2.29	0.00	2.29
	Total Segment Profit Before Tax	6.28	73.42	9.03	110.95
	Interest Income	0.00	2.18	0.00	2.18
	Interest Expenses	3.75	3.81	3.72	15.06
	Other Unallocable Income net of Expenditure				
	Profit Before Tax	2.53	71.79	5.31	98.07
	Provision for current tax	0.00	18.69	0.00	18.687
	Item Related Earlier Year		1.12		1.121
	Profit After Tax	2.53	51.98	5.31	78.26
3	Capital Employed				
	(Segment Assets- Segment Liabilities)				
	Pharma Unit	391.72	396.16	171.26	396.16
	Chemicals Division	731.58	722.23	553.95	722.23
	Plastic Division	(53.85)	(46.41)	(36.19)	(46.41)
	Other	0.00	0.00	0.00	-
	Total Capital Employed	1069.45	1071.99	689.01	1071.99

DATE : 10-08-2016

PLACE : INDORE

BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

RAMESH SHAH
MANAGING DIRECTOR
(DIN NO. 00028819)





S.N. Gadiya & Co.
(Chartered Accountants)

Limited Review Report

Satya Narayan Gadiya
F.C.A., B. Com.
Mob. : 9301503126

The Board of Directors,
M/S Biofil Chemicals And Pharmaceuticals Limited
11/12, Sector E Sanwer Road
Industrial Area
Indore-452015 -M.P.

We have reviewed the accompanying statement of unaudited financial results (the "Statement") of Biofil Chemicals and Pharmaceuticals Limited ("the Company") for the quarter ended 30th June 2016 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.N. Gadiya & Co.
Chartered Accountants
FRN: 002052C

S.N. Gadiya
Proprietor
M. No.071229

Date 10.08.2016
Place:-Indore



241, Apollo Tower, 2, M.G. Road, Indore-1 Ph. : 07314069030
Resi. : 15, Textile Clerk Colony, Indore-10 Ph. : 07314031266
E-mail : satya_mewar@rediffmail.com